ES2525137A2 - Agentes para tratar el mieloma múltiple - Google Patents

Agentes para tratar el mieloma múltiple Download PDF

Info

Publication number
ES2525137A2
ES2525137A2 ES201330884A ES201330884A ES2525137A2 ES 2525137 A2 ES2525137 A2 ES 2525137A2 ES 201330884 A ES201330884 A ES 201330884A ES 201330884 A ES201330884 A ES 201330884A ES 2525137 A2 ES2525137 A2 ES 2525137A2
Authority
ES
Spain
Prior art keywords
compounds
multiple myeloma
agents
treating multiple
cannabinoid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES201330884A
Other languages
English (en)
Other versions
ES2525137B1 (es
ES2525137R2 (es
Inventor
José Antonio PÉREZ SIMON
Mª Victoria BARBADO GONZÁLEZ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Servicio Andaluz de Salud
Original Assignee
Servicio Andaluz de Salud
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servicio Andaluz de Salud filed Critical Servicio Andaluz de Salud
Priority to ES201330884A priority Critical patent/ES2525137B1/es
Priority to US14/897,333 priority patent/US10045994B2/en
Priority to EP14811341.8A priority patent/EP3009131A4/en
Priority to CN201480044443.9A priority patent/CN105682651A/zh
Priority to PCT/ES2014/070491 priority patent/WO2014198993A1/es
Publication of ES2525137A2 publication Critical patent/ES2525137A2/es
Publication of ES2525137R2 publication Critical patent/ES2525137R2/es
Application granted granted Critical
Publication of ES2525137B1 publication Critical patent/ES2525137B1/es
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere al uso de compuestos de naturaleza cannabinoide para inhibir la viabilidad a dosis crecientes de líneas celulares del mieloma. Adicionalmente, estos mismos compuestos han demostrado no afectar, en términos de viabilidad y proliferación, las células CD34+ (progenitores hematopoyéticos normales). Por lo tanto, esta invención abre las puertas a la utilización de compuestos de naturaleza cannabinoide como una terapia prometedora frente al mieloma múltiple y enfermedades relacionadas.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19
imagen20
imagen21
imagen22
imagen23
imagen24

Claims (1)

  1. imagen1
    imagen2
    imagen3
    imagen4
    imagen5
ES201330884A 2013-06-13 2013-06-13 Agentes para tratar el mieloma múltiple Expired - Fee Related ES2525137B1 (es)

Priority Applications (5)

Application Number Priority Date Filing Date Title
ES201330884A ES2525137B1 (es) 2013-06-13 2013-06-13 Agentes para tratar el mieloma múltiple
US14/897,333 US10045994B2 (en) 2013-06-13 2014-06-13 Agents for treating multiple myeloma
EP14811341.8A EP3009131A4 (en) 2013-06-13 2014-06-13 Agents for treating multiple myeloma
CN201480044443.9A CN105682651A (zh) 2013-06-13 2014-06-13 用于治疗多发性骨髓瘤的试剂
PCT/ES2014/070491 WO2014198993A1 (es) 2013-06-13 2014-06-13 Agentes para tratar el mieloma múltiple

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201330884A ES2525137B1 (es) 2013-06-13 2013-06-13 Agentes para tratar el mieloma múltiple

Publications (3)

Publication Number Publication Date
ES2525137A2 true ES2525137A2 (es) 2014-12-17
ES2525137R2 ES2525137R2 (es) 2015-01-12
ES2525137B1 ES2525137B1 (es) 2016-01-18

Family

ID=52016900

Family Applications (1)

Application Number Title Priority Date Filing Date
ES201330884A Expired - Fee Related ES2525137B1 (es) 2013-06-13 2013-06-13 Agentes para tratar el mieloma múltiple

Country Status (5)

Country Link
US (1) US10045994B2 (es)
EP (1) EP3009131A4 (es)
CN (1) CN105682651A (es)
ES (1) ES2525137B1 (es)
WO (1) WO2014198993A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015020332A2 (pt) * 2013-02-28 2017-07-18 Full Spectrum Laboratories Ltd processos de engenharia química e aparelhos para a síntese de compostos
AU2015308136B2 (en) 2014-08-25 2020-07-09 Teewinot Technologies Limited Apparatus and methods for the simultaneous production of cannabinoid compounds
WO2016084075A1 (en) * 2014-11-26 2016-06-02 One World Cannabis Ltd Synergistic use of cannabis for treating multiple myeloma
WO2016087649A2 (en) * 2014-12-04 2016-06-09 Servicio Andaluz De Salud Use of cannabinoids as ceramide-generating anticancer agents in tumors of the hematopoietic and lymphoid tissues
CA2988869A1 (en) * 2015-06-11 2016-12-15 One World Cannabis Ltd Novel cannabinoid combination therapies for multiple myeloma (mm)
GB201916846D0 (en) * 2019-11-19 2020-01-01 Gw Res Ltd Cannabidiol-type cannabinoid compound
AU2022324615A1 (en) 2021-08-04 2024-02-15 Demeetra Agbio, Inc. Cannabinoid derivatives and their use
CN115583933B (zh) * 2022-10-31 2024-02-06 暨明医药科技（苏州）有限公司 一种高纯度四氢大麻素同系物的制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8772541B2 (en) * 2011-12-15 2014-07-08 University of Pittsburgh—of the Commonwealth System of Higher Education Cannabinoid receptor 2 (CB2) inverse agonists and therapeutic potential for multiple myeloma and osteoporosis bone diseases
EP2719375A1 (en) 2012-10-10 2014-04-16 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Cannabinoids for the treatment of cancers dependent on hedgehog mechanisms

Also Published As

Publication number Publication date
CN105682651A (zh) 2016-06-15
EP3009131A4 (en) 2017-01-25
US10045994B2 (en) 2018-08-14
ES2525137B1 (es) 2016-01-18
WO2014198993A1 (es) 2014-12-18
EP3009131A1 (en) 2016-04-20
ES2525137R2 (es) 2015-01-12
US20160120874A1 (en) 2016-05-05

Similar Documents

Publication Publication Date Title
ES2525137A2 (es) Agentes para tratar el mieloma múltiple
CU20170172A7 (es) 4,6-diaminoquinolin-3-carbonitrilos sustituidos útiles como agentes analgésicos, antipiréticos o antiinflamatorios y antineoplásicos
GT201500051A (es) Inhibidores de glucosilceramida sintasa
CR20150376A (es) Compuestos sustituidos de pirrolopirimidina, compuestos de los mismos y metodos de tratamiento con los mismos
CL2016000807A1 (es) Amino heteroarilo benzamidas como inhibidores de quinasa.
CL2015002472A1 (es) Como inhibidores de mutant idh-yl-oxazolidin-2-onas 3-pirimidin-4.
CL2015003280A1 (es) Derivados de benzimidazol como inhibidores de bromodominio
CL2015002151A1 (es) Biaril amide compuestos como inhibidores de quinasa
CL2015000942A1 (es) Compuestos de benceno sustituido.
DK3492455T3 (da) 1,2,4-triazoler som nukleare transportmodulatorer og anvendelse til behandling af specifikke former for cancer
CL2016000241A1 (es) Formulación de inhibidores de la syk.
RS53818B1 (en) PIROLOBENZODIAZEPINI I NJIHOVI conjugated
CL2016001266A1 (es) Nuevo octahidro-ciclobuta[1,2-c;3,4-c']dipirrol-2-ilo.
MX362442B (es) Inhibidores de enzima 1 dependiente de inositol (ire-1alfa).
BR112016002287A2 (pt) compostos terapeuticamente ativos e seus métodos de uso
GT201300215A (es) Inhibidores de glucosilceramida sintasa
MX2015009105A (es) Composiciones en solucion solida y su uso en inflamacion cronica.
UY34571A (es) Composiciones herbicidas que contienen bentazón y el inhibidor als y el inhibidor accasa.
CR20170076A (es) Derivados de pirimidima sustituidos con heterociclilo opcionalmente condensados útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias
MX366317B (es) Composiciones y metodos para tratar la inflamacion cronica y las enfermedades inflamatorias.
UY34775A (es) Uso de laquinimod en alta dosis para el tratamiento de la esclerosis múltiple
UY34200A (es) 3-(fluorovinil)pirazoles y su uso
RS53893B1 (en) USE OF BIOTIN FOR MULTIPLE SCLEROSIS TREATMENT
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
PE20151435A1 (es) Laquinimod para reducir el dano talamico en la esclerosis multiple

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2525137

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20160118

FD2A Announcement of lapse in spain

Effective date: 20210915